62 related articles for article (PubMed ID: 15451427)
1. Unexpected Role of MPO-Oxidized LDLs in Atherosclerosis: In between Inflammation and Its Resolution.
Tangeten C; Zouaoui Boudjeltia K; Delporte C; Van Antwerpen P; Korpak K
Antioxidants (Basel); 2022 Apr; 11(5):. PubMed ID: 35624738
[TBL] [Abstract][Full Text] [Related]
2. Role of myeloperoxidase in inflammation and atherosclerosis (Review).
Frangie C; Daher J
Biomed Rep; 2022 Jun; 16(6):53. PubMed ID: 35620311
[TBL] [Abstract][Full Text] [Related]
3. Mass Spectrometry for the Monitoring of Lipoprotein Oxidations by Myeloperoxidase in Cardiovascular Diseases.
Coremans C; Delporte C; Cotton F; Van De Borne P; Boudjeltia KZ; Van Antwerpen P
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500696
[TBL] [Abstract][Full Text] [Related]
4. Insight Into the Prospects for RNAi Therapy of Cancer.
Tian Z; Liang G; Cui K; Liang Y; Wang Q; Lv S; Cheng X; Zhang L
Front Pharmacol; 2021; 12():644718. PubMed ID: 33796026
[TBL] [Abstract][Full Text] [Related]
5. M2 Monocyte Polarization in Dialyzed Patients Is Associated with Increased Levels of M-CSF and Myeloperoxidase-Associated Oxidative Stress: Preliminary Results.
Pireaux V; Delporte C; Rousseau A; Desmet JM; Van Antwerpen P; Raes M; Zouaoui Boudjeltia K
Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33467199
[TBL] [Abstract][Full Text] [Related]
6. Dapsone protects brain microvascular integrity from high-fat diet induced LDL oxidation.
Zhan R; Zhao M; Zhou T; Chen Y; Yu W; Zhao L; Zhang T; Wang H; Yang H; Jin Y; He Q; Yang X; Guo X; Willard B; Pan B; Huang Y; Chen Y; Chui D; Zheng L
Cell Death Dis; 2018 Jun; 9(6):683. PubMed ID: 29880899
[TBL] [Abstract][Full Text] [Related]
7. Myeloperoxidase-Oxidized LDLs Enhance an Anti-Inflammatory M2 and Antioxidant Phenotype in Murine Macrophages.
Pireaux V; Sauvage A; Bihin B; Van Steenbrugge M; Rousseau A; Van Antwerpen P; Zouaoui Boudjeltia K; Raes M
Mediators Inflamm; 2016; 2016():8249476. PubMed ID: 27656049
[TBL] [Abstract][Full Text] [Related]
8. Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100.
Delporte C; Boudjeltia KZ; Noyon C; Furtmüller PG; Nuyens V; Slomianny MC; Madhoun P; Desmet JM; Raynal P; Dufour D; Koyani CN; Reyé F; Rousseau A; Vanhaeverbeek M; Ducobu J; Michalski JC; Nève J; Vanhamme L; Obinger C; Malle E; Van Antwerpen P
J Lipid Res; 2014 Apr; 55(4):747-57. PubMed ID: 24534704
[TBL] [Abstract][Full Text] [Related]
9. Characterization and antioxidant properties of six Algerian propolis extracts: ethyl acetate extracts inhibit myeloperoxidase activity.
Boufadi YM; Soubhye J; Riazi A; Rousseau A; Vanhaeverbeek M; Nève J; Boudjeltia KZ; Van Antwerpen P
Int J Mol Sci; 2014 Feb; 15(2):2327-45. PubMed ID: 24514562
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies.
Delporte C; Van Antwerpen P; Vanhamme L; Roumeguère T; Zouaoui Boudjeltia K
Mediators Inflamm; 2013; 2013():971579. PubMed ID: 23983406
[TBL] [Abstract][Full Text] [Related]
11. Exposure of endothelial cells to physiological levels of myeloperoxidase-modified LDL delays pericellular fibrinolysis.
Zouaoui Boudjeltia K; Daher J; Van Antwerpen P; Moguilevsky N; Delree P; Ducobu J; Raes M; Badran B; Vanhaeverbeek M; Brohee D; Remacle C; Vanhamme L
PLoS One; 2012; 7(6):e38810. PubMed ID: 22723891
[TBL] [Abstract][Full Text] [Related]
12. Temporal dissociation between myeloperoxidase (MPO)-modified LDL and MPO elevations during chronic sleep restriction and recovery in healthy young men.
Boudjeltia KZ; Faraut B; Esposito MJ; Stenuit P; Dyzma M; Antwerpen PV; Brohée D; Vanhamme L; Moguilevsky N; Vanhaeverbeek M; Kerkhofs M
PLoS One; 2011; 6(11):e28230. PubMed ID: 22140557
[TBL] [Abstract][Full Text] [Related]
13. Glycosylation pattern of mature dimeric leukocyte and recombinant monomeric myeloperoxidase: glycosylation is required for optimal enzymatic activity.
Van Antwerpen P; Slomianny MC; Boudjeltia KZ; Delporte C; Faid V; Calay D; Rousseau A; Moguilevsky N; Raes M; Vanhamme L; Furtmüller PG; Obinger C; Vanhaeverbeek M; Nève J; Michalski JC
J Biol Chem; 2010 May; 285(21):16351-9. PubMed ID: 20332087
[TBL] [Abstract][Full Text] [Related]
14. Oxidized low-density lipoprotein.
Parthasarathy S; Raghavamenon A; Garelnabi MO; Santanam N
Methods Mol Biol; 2010; 610():403-17. PubMed ID: 20013192
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of the humoral immune response to modified LDL.
Lopes-Virella MF; Virella G
Clin Immunol; 2010 Jan; 134(1):55-65. PubMed ID: 19427818
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions.
Moguilevsky N; Zouaoui Boudjeltia K; Babar S; Delrée P; Legssyer I; Carpentier Y; Vanhaeverbeek M; Ducobu J
Biochem Biophys Res Commun; 2004 Oct; 323(4):1223-8. PubMed ID: 15451427
[TBL] [Abstract][Full Text] [Related]
17. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.
Holvoet P; Perez G; Zhao Z; Brouwers E; Bernar H; Collen D
J Clin Invest; 1995 Jun; 95(6):2611-9. PubMed ID: 7769103
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis.
Schiopu A; Bengtsson J; Söderberg I; Janciauskiene S; Lindgren S; Ares MP; Shah PK; Carlsson R; Nilsson J; Fredrikson GN
Circulation; 2004 Oct; 110(14):2047-52. PubMed ID: 15451805
[TBL] [Abstract][Full Text] [Related]
19. Studying low-density lipoprotein-monoclonal antibody complexes using dynamic laser light scattering and analytical ultracentrifugation.
Gutierrez MM; Tsai SW; Phillips ML; Curtiss LK; Milne RW; Schumaker VN
Biochemistry; 1999 Jan; 38(4):1284-92. PubMed ID: 9930989
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
